316 results on '"Sweetenham, J."'
Search Results
2. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
3. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
4. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation
5. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
6. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT
7. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
8. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
9. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation
10. Stromal gene signatures in large-B-cells lymphomas
11. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
12. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia
13. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies
14. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
15. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study
16. Current therapies in Hodgkin's disease
17. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma
18. Apheresis days required for harvesting CD34 + cells predicts hematopoietic recovery and survival following autologous transplantation
19. 25 Factors Associated with Emergency Department Use among Adults with Newly Diagnosed Cancer
20. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
21. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation
22. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue
23. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies
24. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa
25. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma
26. Autologous stem cell transplantation for malignancy: a systematic review of the literature
27. The Imaging of Burkitt's and Burkitt-like Lymphoma
28. IMMUNOTHERAPY OF MANTLE CELL LYMPHOMA (MCL), LYMPHOPLASMACYTOID LYMPHOMA (LPC) AND WALDENSTROM'S MACROGLOBULINEMIA (WM), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH RITUXIMAB (IDEC-C288): PRELIMINARY RESULTS OF AN ONGOING INTERNATIONAL MULTICENTRE TRIAL
29. HAEMOPOIETIC PROGENITOR HOMING AND MOBILIZATION
30. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix
31. Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas.
32. Lymphomas
33. Autologous stem cell transplantation for malignancy: a systematic review of the literature
34. Lymphoma
35. Immunogenicity of Polysaccharide Pneumococcal Vaccination in Autologous Hematopoietic Stem Cell Transplantation
36. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
37. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
38. Pancreatitis in Germ Cell Tumors
39. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
40. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT
41. Busulfan and Cyclophosphamide has Similar Outcomes to High Dose Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation In Patients With Multiple Myeloma
42. Minimal Mortality from Veno-Occlusive Disease Following Busulfan-Based Preparative Regimens: A Large Single Institution Experience
43. CD34+ Cell Yield on Day 1 of Apheresis Predicts Total CD34+ Cell Mobilization, Neutrophil Recovery, and Survival After Autologous Stem Cell Transplantation for Lymphoma
44. T-Cell Engraftment Kinetics Following Myeloablative and Nonmyeloablative Regimens for Allogeneic Hematopoietic Transplantation
45. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
46. Ocular adnexal lymphoma. What is the evidence for an infectious aetiology?
47. 174: Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma
48. 294: Predictors and Impact of Donor T-cell Chimerism in Myeloablative Allogeneic Stem Cell Transplantation
49. The inclusion of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of follicular lymphoma (FL) is associated with prolonged overall survival (OS) from diagnosis
50. 60: A high lactate dehydrogenase (LDH) level predicts for shorter survival following HLA-matched sibling bone marrow transplant (BMT) for patients with acute myelogenous leukemia (AML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.